Difficulty: Intermediate | Prerequisites: Part 1 of these notes (symptoms, diagnosis, DSM-5 criteria for schizophrenia).
Big picture: Schizophrenia does not exist in isolation. It sits at the severe end of a continuum of psychotic disorders, each defined by how long symptoms last and how much mood involvement there is. This section covers the other disorders on that spectrum (schizoaffective, schizophreniform, brief psychotic, delusional, schizotypal personality) and then turns to the biological side: what causes schizophrenia at the level of genes, brain structure, prenatal development, and neurotransmitters. The recurring theme is that no single factor explains the disorder; it is a neurodevelopmental condition shaped by many interacting biological risks.
Psychotic disorders form a severity continuum: schizophrenia is the most disabling, followed by schizoaffective, schizophreniform, brief psychotic, and delusional disorder. Schizotypal personality disorder shares genetic and neurological overlap with schizophrenia. Biologically, schizophrenia involves polygenic risk, structural brain abnormalities (reduced grey matter, enlarged ventricles, prefrontal and hippocampal dysfunction), prenatal insults (birth complications, viral exposure), and neurotransmitter imbalances centred on dopamine but also involving serotonin, glutamate, and GABA.
Schizoaffective disorder
A condition combining features of schizophrenia (psychotic symptoms meeting Criterion A) with a prominent mood episode (major depressive or manic). In simple terms, the person has both a psychotic disorder and a mood disorder running concurrently.
Schizophreniform disorder
Meets the same Criterion A as schizophrenia, but the total episode lasts between 1 month and less than 6 months. Think of it as "schizophrenia that hasn't lasted long enough for a full diagnosis yet." About two-thirds eventually receive a schizophrenia diagnosis.
Brief psychotic disorder
Sudden onset of psychotic symptoms lasting at least 1 day but less than 1 month, with eventual return to premorbid functioning. Think of it as a short, intense psychotic break, often triggered by extreme stress.
Delusional disorder
The presence of one or more delusions lasting 1+ month, without the other major symptoms of schizophrenia. Functioning is not markedly impaired outside the scope of the delusion itself. In simple terms, the person's life is relatively normal except for this one fixed, false belief system.
Schizotypal personality disorder
A lifelong pattern of oddities in self-concept, interpersonal relating, thinking, and behaviour that shares genetic, neurological, and cognitive features with schizophrenia. In simple terms, it looks like a mild, chronic, personality-level version of some schizophrenia traits. Some individuals eventually develop full schizophrenia.
Mesolimbic pathway
The subcortical dopamine pathway involved in processing salience and reward. In schizophrenia, excess dopamine activity here is thought to drive positive symptoms by causing the brain to flag irrelevant stimuli as important.
Prefrontal cortex
The brain region critical for language, emotional expression, planning, and carrying out goals. In schizophrenia it tends to be unusually small or underactive, which is associated with negative symptoms and cognitive deficits.
Phenothiazines / neuroleptics
The first class of antipsychotic drugs (e.g. chlorpromazine). They work by blocking dopamine receptors, reducing positive symptoms.
Atypical antipsychotics
Newer drugs (e.g. clozapine, risperidone, olanzapine) that bind to specific dopamine receptor subtypes and also affect serotonin. They are more effective at treating both positive and negative symptoms, with a different side-effect profile.
Agranulocytosis
A potentially fatal deficiency of granulocytes (infection-fighting white blood cells) that occurs in 1–2% of patients taking clozapine. Requires regular blood monitoring.
Tardive dyskinesia
Involuntary, repetitive movements of the tongue, face, mouth, or jaw caused by long-term use of typical antipsychotics (phenothiazines). It is irreversible in about 20% of long-term users.
Hypoxia
Oxygen deprivation at birth or in the surrounding weeks, found in approximately 30% of people who later develop schizophrenia.
The disorders below form a continuum of severity. Schizophrenia has the worst long-term outcome, followed by schizoaffective disorder, schizophreniform disorder, and then the rest.
A blend of schizophrenia and a mood disorder: the person experiences psychotic symptoms alongside a major depressive or manic episode
DSM-5 criteria:
A. An uninterrupted illness period with a major mood episode occurring concurrently with Criterion A of schizophrenia
B. Delusions or hallucinations for 2+ weeks in the absence of a mood episode during the lifetime of the illness (this is the key differentiator from a mood disorder with psychotic features)
C. Mood symptoms are present for the majority of the total active and residual illness duration
D. Not attributable to substances or another medical condition
Specified as bipolar type (manic episodes present) or depressive type (only depressive episodes)
Meets Criteria A, D, and E of schizophrenia, but the episode lasts 1+ month and less than 6 months
Diagnosis is "provisional" if made before recovery
Good prognostic features (2+ of): rapid onset of psychotic symptoms within 4 weeks of first behavioural change, confusion or perplexity, good premorbid functioning, absence of flat affect
Two-thirds of people with this diagnosis eventually meet criteria for schizophrenia
Sudden onset, lasting 1+ day but less than 1 month, with return to premorbid functioning
Requires 1+ of: delusions, hallucinations, disorganised speech, or catatonic behaviour (at least one must be delusions, hallucinations, or disorganised speech)
Occurs in approximately 1 in 10,000 women postpartum; risk of relapse is high but most show excellent outcomes
Specifiers: with marked stressors (brief reactive psychosis), without marked stressors, with postpartum onset, with catatonia
Lifetime prevalence of 0.2%, more common in females, with first psychiatric admission typically at age 40–49 (later than most disorders)
DSM-5 criteria:
A. 1+ delusions lasting 1+ month
B. Full Criterion A of schizophrenia has never been met (hallucinations, if present, are not prominent and are related to the delusional theme)
C. Functioning is not markedly impaired and behaviour is not bizarre outside the delusion
D. Any mood episodes have been brief relative to the delusional periods
E. Not attributable to another condition
Types: erotomanic (someone is in love with them), grandiose, jealous, persecutory, somatic, unspecified
Specifier: with bizarre content (clearly implausible, not derived from ordinary experiences)
A lifelong pattern of oddities in self-concept, relating to others, thinking, and behaviour
Shares genetic traits, neurological abnormalities, and cognitive deficits with schizophrenia; some individuals eventually develop the full disorder
Classified as a personality disorder
DSM-5 criteria: 5+ of the following, present since early adulthood across multiple contexts:
Ideas of reference
Odd beliefs or magical thinking
Unusual perceptual experiences (including body illusions)
Odd thinking and speech
Suspiciousness or paranoid ideation
Inappropriate or constricted affect
Odd, eccentric, or peculiar behaviour/appearance
Lack of close friends outside first-degree relatives
Excessive social anxiety that does not diminish with familiarity, driven by paranoid thinking rather than negative self-judgement
Does not occur exclusively during the course of another disorder
If criteria are met before schizophrenia onset, the specifier "premorbid" is added
No single gene accounts for schizophrenia. Different genes contribute to different symptom domains
Gottesman's summary of 40 studies on lifetime risk:
Children of two parents with schizophrenia and monozygotic (MZ) twins share the greatest genetic overlap and the highest risk
First-degree relatives (50% shared genes): approximately 10% risk
Nieces/nephews (25% shared genes): approximately 3% risk
General population: 1–2% risk
87% of children with one parent with schizophrenia will not develop it
63% of people with schizophrenia have no first- or second-degree relative with the disorder
Adoption studies help separate genetic from environmental influences:
Kety: biological relatives of adoptees with schizophrenia were 10x more likely to have schizophrenia than biological relatives of adoptees without it. Adoptive relatives showed no increased risk
Tienari: 10% of children whose biological mother had schizophrenia developed a psychotic disorder, compared to 1% of children whose biological mother did not
Most theorists view schizophrenia as a neurodevelopmental disorder in which abnormal brain development begins in utero and early life
Grey matter reduction in the cortex: medial, temporal, superior temporal, and prefrontal areas
Prefrontal cortex:
Important for language, emotional expression, planning, executing plans
Connects to all other cortical regions and the limbic system
Unusually small or inactive in people with schizophrenia and those at risk
Abnormal development in adolescence may explain why schizophrenia often emerges in the late teens/early 20s
Hippocampus:
Abnormal activation during memory encoding and retrieval tasks
Critical for long-term memory formation
Similar abnormalities found in first-degree relatives
White matter:
Reductions and abnormalities in the connections between brain regions, particularly associated with working memory deficits
These appear to be early signs of the disorder, not consequences
Enlarged ventricles (fluid-filled brain spaces), indicating atrophy of surrounding tissue, associated with more severe symptoms
Birth complications:
Serious prenatal and birth difficulties are more common in people who later develop schizophrenia
Obstetric difficulties increase the likelihood of developing the full syndrome
Hypoxia (oxygen deprivation at or near birth) is found in about 30% of people with schizophrenia, though most people who experience perinatal hypoxia do not develop the disorder
Prenatal viral exposure:
Higher rates of schizophrenia in children whose mothers were exposed to viral infections during pregnancy, especially during the second trimester (a crucial period for CNS development)
People with schizophrenia are somewhat more likely to have been born in spring (conception during autumn/winter flu season)
Famine in China doubled the risk of schizophrenia in offspring
Herpes simplex virus during pregnancy is linked to increased risk
The mechanism: viral infections activate the mother's immune system, which can disrupt development of brain cells and dopamine systems in the foetus
Dopamine:
The original dopamine hypothesis: schizophrenia symptoms are caused by excess dopamine, particularly in the prefrontal cortex and limbic system
Evidence supporting this:
Drugs that block dopamine reuptake (phenothiazines/neuroleptics) reduce symptoms
Drugs that increase dopamine (amphetamines) worsen positive symptoms
Neuroimaging shows more dopamine receptors and higher dopamine levels in certain brain regions
The original theory proved too simple. Antipsychotics relieve positive symptoms more than negative ones, suggesting dopamine is not the whole story
Davis's revised theory: different dopamine receptor types and different dopamine levels in different brain areas account for different symptoms:
Mesolimbic pathway: excess dopamine activity drives positive symptoms by making the brain attribute importance to irrelevant stimuli
Prefrontal cortex: unusually low dopamine is associated with negative symptoms (attention, motivation, behavioural organisation). This explains why phenothiazines do not effectively treat negative symptoms
Key brain areas with abnormal dopamine activity: ventral tegmental area, prefrontal cortex, mesolimbic pathway, amygdala, hypothalamus, hippocampus
Serotonin:
Serotonin neurons regulate dopamine neurons in the mesolimbic system
Some newer drugs (atypical antipsychotics) bind to serotonin receptors
Glutamate and GABA:
Abnormal levels of both contribute to cognitive and emotional symptoms
Glutamate neurons form the major excitatory pathways linking cortex, limbic system, and thalamus, regions that function abnormally in schizophrenia
Drugs that block glutamate receptors (PCP, ketamine) cause hallucinations and delusions in otherwise healthy people, supporting the glutamate hypothesis
The dopamine hypothesis directly explains why street drugs like amphetamines and methamphetamine can trigger psychotic episodes in vulnerable people, and why emergency departments screen for substance use before diagnosing a psychotic disorder. Understanding the role of prenatal viral exposure has public health implications: maternal flu vaccination during pregnancy may reduce one risk factor for schizophrenia. The genetic research clarifies why schizophrenia "runs in families" without following a simple inheritance pattern, which matters for genetic counselling.
"If a relative has schizophrenia, I will probably get it too." Even with one parent affected, 87% of children do not develop the disorder. Most people with schizophrenia have no close relatives with it.
"Schizophrenia is caused by too much dopamine, full stop." The original dopamine hypothesis was too simple. The revised model involves excess dopamine in the mesolimbic pathway (positive symptoms) and too little dopamine in the prefrontal cortex (negative symptoms), plus contributions from serotonin, glutamate, and GABA.
"Schizophreniform disorder is just mild schizophrenia." The difference is duration (less than 6 months), not severity. Two-thirds of people with schizophreniform disorder go on to meet full schizophrenia criteria.
"Delusional disorder is a type of schizophrenia." It is a separate diagnosis. Functioning is largely intact outside the delusion, hallucinations are absent or minor, and the other Criterion A symptoms of schizophrenia are not met.
Know the duration cutoffs that distinguish schizophrenia (6+ months), schizophreniform (1–6 months), and brief psychotic disorder (1 day to 1 month)
Schizoaffective disorder requires psychotic symptoms in the absence of a mood episode for at least 2 weeks during the lifetime of the illness; this is the critical criterion that separates it from a mood disorder with psychotic features
The Gottesman adoption-study statistics (10x risk in biological relatives, no increased risk in adoptive relatives) are commonly tested
Davis's revised dopamine theory (excess in mesolimbic = positive symptoms; deficit in prefrontal = negative symptoms) is a frequent exam point
Prenatal risk factors (viral exposure, hypoxia, famine) and the second-trimester vulnerability window
Glutamate's role: PCP and ketamine blocking glutamate receptors causes psychotic symptoms in healthy people
True or False: Schizoaffective disorder requires that psychotic symptoms be present for at least 2 weeks in the absence of a mood episode.
Fill in the blank: Schizophreniform disorder has the same Criterion A as schizophrenia but lasts between 1 month and less than __________ months.
True or False: In delusional disorder, the person's functioning is markedly impaired across all areas of life.
True or False: Adoptive relatives of adoptees with schizophrenia show increased risk of developing the disorder.
Fill in the blank: Excess dopamine in the __________ pathway is associated with positive symptoms, while low dopamine in the __________ cortex is associated with negative symptoms.
(Answers: 1. True; 2. six; 3. False, functioning is not markedly impaired apart from the impact of the delusion itself; 4. False, only biological relatives show increased risk; 5. mesolimbic, prefrontal.)
Q: What is the key criterion that distinguishes schizoaffective disorder from major depression or bipolar disorder with psychotic features?
A: In schizoaffective disorder, delusions or hallucinations must be present for at least 2 weeks during the lifetime of the illness in the absence of a major mood episode. In mood disorders with psychotic features, psychotic symptoms only occur during mood episodes.
Q: Explain Davis's revised dopamine theory of schizophrenia.
A: Davis proposed that different dopamine receptor types and dopamine levels in different brain regions account for different symptom clusters. Excess dopamine in the mesolimbic pathway causes the brain to attribute salience to irrelevant stimuli, producing positive symptoms. Unusually low dopamine in the prefrontal cortex impairs attention, motivation, and behavioural organisation, producing negative symptoms. This explains why typical antipsychotics (which reduce dopamine globally) help positive symptoms but not negative ones.
Q: How do adoption studies support the genetic contribution to schizophrenia?
A: Kety found that biological relatives of adoptees with schizophrenia were 10 times more likely to have schizophrenia themselves, while adoptive relatives showed no increased risk. Tienari found that 10% of adopted children whose biological mothers had schizophrenia developed a psychotic disorder, compared to 1% whose biological mothers did not. Because these children were raised away from their biological parents, the findings point to genetic rather than environmental transmission.
Q: Name three prenatal or perinatal risk factors for schizophrenia.
A: Birth complications and perinatal hypoxia (oxygen deprivation), maternal exposure to viral infections during pregnancy (especially the second trimester), and maternal famine or malnutrition during pregnancy.
Q: What differentiates schizotypal personality disorder from schizophrenia on the spectrum?
A: Schizotypal personality disorder is a lifelong personality pattern of oddities in thinking, perception, and relating, without full-blown psychotic episodes. It shares genetic, neurological, and cognitive features with schizophrenia, but symptoms are attenuated and stable rather than episodic and severe. Some individuals with schizotypal personality disorder eventually develop full schizophrenia.
This section connects to personality disorders (schizotypal personality disorder is classified under Cluster A). It also ties into behavioural genetics and research methods (twin studies, adoption studies). The neurotransmitter material links to psychopharmacology and to substance-related disorders (amphetamine-induced psychosis, PCP/ketamine effects). Prenatal risk factors connect to developmental psychology and public health.
schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, schizotypal personality disorder, psychotic disorder continuum, DSM-5 psychotic disorders, dopamine hypothesis, revised dopamine theory, mesolimbic pathway, prefrontal cortex, atypical antipsychotics, phenothiazines, neuroleptics, grey matter reduction, enlarged ventricles, hippocampus schizophrenia, white matter abnormalities, prenatal viral exposure, birth complications, hypoxia, perinatal risk, serotonin, glutamate, GABA, PCP ketamine psychosis, Gottesman, Kety adoption study, Tienari adoption study, Davis dopamine theory, neurodevelopmental disorder, genetic risk schizophrenia, abnormal psychology chapter 8